 Fabrice Dabertrand
Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arterioles | 8 | 2025 | 52 | 2.620 |
Why?
| | Vasoconstriction | 6 | 2025 | 202 | 2.350 |
Why?
| | Ryanodine Receptor Calcium Release Channel | 11 | 2014 | 73 | 2.150 |
Why?
| | Calcium Signaling | 12 | 2025 | 249 | 2.000 |
Why?
| | Cerebrovascular Circulation | 8 | 2025 | 243 | 1.720 |
Why?
| | Capillaries | 3 | 2025 | 108 | 1.640 |
Why?
| | Hippocampus | 3 | 2025 | 895 | 1.550 |
Why?
| | Potassium Channels, Inwardly Rectifying | 6 | 2021 | 38 | 1.280 |
Why?
| | Potassium Channels, Voltage-Gated | 3 | 2020 | 50 | 1.260 |
Why?
| | Muscle, Smooth, Vascular | 8 | 2025 | 446 | 1.230 |
Why?
| | Brain | 9 | 2025 | 2668 | 1.080 |
Why?
| | Cerebral Small Vessel Diseases | 3 | 2021 | 5 | 1.070 |
Why?
| | TRPC Cation Channels | 2 | 2025 | 14 | 0.970 |
Why?
| | Small-Conductance Calcium-Activated Potassium Channels | 1 | 2025 | 12 | 0.950 |
Why?
| | Heparin-binding EGF-like Growth Factor | 3 | 2020 | 16 | 0.940 |
Why?
| | Pericytes | 1 | 2025 | 34 | 0.920 |
Why?
| | Hyperemia | 2 | 2021 | 49 | 0.870 |
Why?
| | Neurovascular Coupling | 3 | 2020 | 9 | 0.850 |
Why?
| | Phosphatidylinositol 4,5-Diphosphate | 2 | 2021 | 32 | 0.840 |
Why?
| | Myocytes, Smooth Muscle | 6 | 2020 | 261 | 0.780 |
Why?
| | Estrogens | 1 | 2025 | 367 | 0.760 |
Why?
| | Muscle Cells | 3 | 2011 | 43 | 0.750 |
Why?
| | Endothelium, Vascular | 3 | 2025 | 927 | 0.750 |
Why?
| | Microvessels | 3 | 2021 | 88 | 0.720 |
Why?
| | Microcirculation | 3 | 2020 | 149 | 0.710 |
Why?
| | Blood Pressure | 3 | 2025 | 1786 | 0.680 |
Why?
| | Duodenum | 3 | 2009 | 78 | 0.660 |
Why?
| | Calcium | 8 | 2025 | 1199 | 0.660 |
Why?
| | Mice | 23 | 2025 | 17787 | 0.560 |
Why?
| | Endothelial Cells | 6 | 2024 | 785 | 0.560 |
Why?
| | Membrane Potentials | 5 | 2025 | 284 | 0.550 |
Why?
| | Animals | 31 | 2025 | 36940 | 0.510 |
Why?
| | Cerebrovascular Disorders | 1 | 2015 | 96 | 0.430 |
Why?
| | Potassium Channels | 1 | 2015 | 151 | 0.430 |
Why?
| | Mice, Inbred C57BL | 11 | 2025 | 5757 | 0.430 |
Why?
| | Cerebral Cortex | 2 | 2016 | 433 | 0.420 |
Why?
| | Muscle Tonus | 1 | 2013 | 21 | 0.410 |
Why?
| | Gentamicins | 2 | 2009 | 54 | 0.390 |
Why?
| | Dinoprostone | 1 | 2013 | 191 | 0.380 |
Why?
| | Pia Mater | 1 | 2011 | 5 | 0.380 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2011 | 10 | 0.370 |
Why?
| | Astrocytes | 2 | 2014 | 210 | 0.370 |
Why?
| | Cerebral Arteries | 4 | 2018 | 59 | 0.360 |
Why?
| | Space Flight | 1 | 2011 | 87 | 0.350 |
Why?
| | Oligonucleotides, Antisense | 5 | 2014 | 112 | 0.340 |
Why?
| | Acidosis | 1 | 2011 | 101 | 0.340 |
Why?
| | Portal Vein | 1 | 2011 | 120 | 0.340 |
Why?
| | Muscle, Smooth | 2 | 2009 | 155 | 0.340 |
Why?
| | Vasodilation | 3 | 2017 | 499 | 0.330 |
Why?
| | Blood-Brain Barrier | 2 | 2024 | 138 | 0.310 |
Why?
| | Exons | 1 | 2009 | 355 | 0.290 |
Why?
| | Hypertension | 2 | 2021 | 1295 | 0.290 |
Why?
| | Alternative Splicing | 2 | 2007 | 229 | 0.280 |
Why?
| | CADASIL | 2 | 2018 | 2 | 0.270 |
Why?
| | Myography | 2 | 2025 | 7 | 0.270 |
Why?
| | Pregnancy, Animal | 1 | 2007 | 52 | 0.270 |
Why?
| | Myometrium | 1 | 2007 | 39 | 0.260 |
Why?
| | Mice, Knockout | 4 | 2025 | 3015 | 0.240 |
Why?
| | Microscopy, Fluorescence, Multiphoton | 1 | 2025 | 67 | 0.230 |
Why?
| | Male | 18 | 2025 | 67762 | 0.230 |
Why?
| | Ovariectomy | 1 | 2025 | 152 | 0.220 |
Why?
| | Nitric Oxide Synthase | 1 | 2025 | 240 | 0.220 |
Why?
| | Mice, Transgenic | 3 | 2021 | 2167 | 0.220 |
Why?
| | Dementia, Vascular | 2 | 2021 | 20 | 0.220 |
Why?
| | Protein Isoforms | 4 | 2014 | 404 | 0.220 |
Why?
| | Myocytes, Cardiac | 1 | 2008 | 526 | 0.210 |
Why?
| | Capillary Permeability | 1 | 2023 | 145 | 0.200 |
Why?
| | Hindlimb Suspension | 2 | 2014 | 20 | 0.200 |
Why?
| | Disease Models, Animal | 5 | 2021 | 4295 | 0.200 |
Why?
| | Potassium | 2 | 2020 | 147 | 0.190 |
Why?
| | Cholesterol | 1 | 2024 | 410 | 0.190 |
Why?
| | Nitric Oxide | 2 | 2025 | 915 | 0.190 |
Why?
| | Microglia | 1 | 2024 | 251 | 0.190 |
Why?
| | Rats | 8 | 2016 | 5647 | 0.180 |
Why?
| | Aging | 2 | 2025 | 1864 | 0.180 |
Why?
| | Membrane Transport Modulators | 1 | 2020 | 7 | 0.170 |
Why?
| | Genetic Variation | 1 | 2006 | 991 | 0.170 |
Why?
| | Aminopyridines | 1 | 2020 | 98 | 0.160 |
Why?
| | Receptor, Notch3 | 2 | 2020 | 5 | 0.160 |
Why?
| | Cerebral Hemorrhage | 1 | 2020 | 108 | 0.150 |
Why?
| | Sex Factors | 1 | 2025 | 2071 | 0.150 |
Why?
| | Hemodynamics | 2 | 2016 | 1113 | 0.150 |
Why?
| | Adaptation, Physiological | 2 | 2014 | 553 | 0.150 |
Why?
| | Genetic Background | 1 | 2018 | 11 | 0.140 |
Why?
| | GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2018 | 20 | 0.140 |
Why?
| | Models, Genetic | 1 | 2020 | 600 | 0.140 |
Why?
| | Antihypertensive Agents | 1 | 2021 | 494 | 0.140 |
Why?
| | rho-Associated Kinases | 1 | 2018 | 83 | 0.140 |
Why?
| | Dilatation | 1 | 2018 | 67 | 0.140 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2018 | 66 | 0.140 |
Why?
| | Tissue Inhibitor of Metalloproteinase-3 | 1 | 2016 | 9 | 0.130 |
Why?
| | Wounds and Injuries | 1 | 2023 | 758 | 0.130 |
Why?
| | ADAM17 Protein | 1 | 2016 | 35 | 0.130 |
Why?
| | Signal Transduction | 5 | 2020 | 5079 | 0.120 |
Why?
| | Catheterization | 1 | 2016 | 179 | 0.120 |
Why?
| | Weightlessness | 2 | 2014 | 45 | 0.120 |
Why?
| | Vascular Diseases | 1 | 2018 | 243 | 0.120 |
Why?
| | 4-Aminopyridine | 1 | 2015 | 24 | 0.120 |
Why?
| | Gene Expression Regulation | 3 | 2009 | 2607 | 0.120 |
Why?
| | Phospholipase C gamma | 1 | 2014 | 29 | 0.110 |
Why?
| | Receptors, Notch | 1 | 2015 | 88 | 0.110 |
Why?
| | Rats, Wistar | 2 | 2014 | 455 | 0.110 |
Why?
| | Cells, Cultured | 3 | 2023 | 4193 | 0.110 |
Why?
| | TRPM Cation Channels | 1 | 2014 | 74 | 0.100 |
Why?
| | Rats, Sprague-Dawley | 3 | 2014 | 2486 | 0.100 |
Why?
| | Neurons | 2 | 2020 | 1590 | 0.100 |
Why?
| | Receptors, Prostaglandin E, EP1 Subtype | 1 | 2013 | 2 | 0.100 |
Why?
| | Calcium Channels, L-Type | 1 | 2014 | 118 | 0.100 |
Why?
| | Mice, Inbred mdx | 2 | 2009 | 12 | 0.100 |
Why?
| | Dystrophin | 2 | 2009 | 35 | 0.100 |
Why?
| | In Vitro Techniques | 2 | 2011 | 1092 | 0.100 |
Why?
| | Calcium Channel Agonists | 1 | 2011 | 12 | 0.090 |
Why?
| | Rats, Inbred WKY | 1 | 2011 | 36 | 0.090 |
Why?
| | TRPV Cation Channels | 2 | 2023 | 40 | 0.090 |
Why?
| | Rats, Inbred SHR | 1 | 2011 | 45 | 0.090 |
Why?
| | KATP Channels | 1 | 2011 | 20 | 0.090 |
Why?
| | Potassium Channel Blockers | 1 | 2011 | 37 | 0.090 |
Why?
| | Corticosterone | 2 | 2014 | 236 | 0.090 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2011 | 204 | 0.090 |
Why?
| | Calcium Channel Blockers | 1 | 2011 | 167 | 0.090 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2011 | 560 | 0.080 |
Why?
| | Tacrolimus Binding Protein 1A | 1 | 2009 | 10 | 0.080 |
Why?
| | Tacrolimus Binding Proteins | 1 | 2009 | 27 | 0.080 |
Why?
| | Glucocorticoids | 1 | 2014 | 594 | 0.080 |
Why?
| | Sulfates | 1 | 2009 | 50 | 0.080 |
Why?
| | Female | 4 | 2025 | 73304 | 0.070 |
Why?
| | Ryanodine | 1 | 2008 | 15 | 0.070 |
Why?
| | Enzyme Inhibitors | 1 | 2011 | 840 | 0.070 |
Why?
| | Sarcoplasmic Reticulum | 1 | 2008 | 46 | 0.070 |
Why?
| | Acetylcholine | 1 | 2008 | 185 | 0.070 |
Why?
| | Cyclic ADP-Ribose | 1 | 2007 | 1 | 0.070 |
Why?
| | Calcium Channels | 1 | 2008 | 159 | 0.070 |
Why?
| | Adipogenesis | 1 | 2007 | 55 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 2057 | 0.070 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2007 | 89 | 0.070 |
Why?
| | Caffeine | 1 | 2007 | 68 | 0.070 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2008 | 220 | 0.060 |
Why?
| | Pituitary-Adrenal System | 1 | 2007 | 162 | 0.060 |
Why?
| | Immunohistochemistry | 3 | 2020 | 1738 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2014 | 976 | 0.060 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2007 | 197 | 0.060 |
Why?
| | Base Sequence | 1 | 2009 | 2181 | 0.060 |
Why?
| | Patch-Clamp Techniques | 2 | 2018 | 286 | 0.060 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2024 | 15 | 0.060 |
Why?
| | Time Factors | 2 | 2014 | 6828 | 0.060 |
Why?
| | Analysis of Variance | 2 | 2018 | 1316 | 0.050 |
Why?
| | Organic Chemicals | 1 | 2024 | 124 | 0.050 |
Why?
| | Amlodipine | 1 | 2021 | 9 | 0.050 |
Why?
| | Inositol 1,4,5-Trisphosphate Receptors | 2 | 2014 | 28 | 0.050 |
Why?
| | Losartan | 1 | 2021 | 14 | 0.050 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2021 | 38 | 0.050 |
Why?
| | Renin-Angiotensin System | 1 | 2021 | 85 | 0.040 |
Why?
| | Humans | 6 | 2023 | 137585 | 0.040 |
Why?
| | Collagen Type IV | 1 | 2020 | 28 | 0.040 |
Why?
| | Retinal Neovascularization | 1 | 2020 | 25 | 0.040 |
Why?
| | Molecular Imaging | 1 | 2020 | 56 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 1066 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 347 | 0.040 |
Why?
| | Retina | 1 | 2020 | 298 | 0.030 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2018 | 220 | 0.030 |
Why?
| | Gene Expression | 1 | 2020 | 1502 | 0.030 |
Why?
| | Vascular Resistance | 1 | 2016 | 375 | 0.030 |
Why?
| | Weightlessness Simulation | 1 | 2014 | 7 | 0.030 |
Why?
| | Genotype | 1 | 2020 | 1916 | 0.030 |
Why?
| | TRPC6 Cation Channel | 1 | 2014 | 3 | 0.030 |
Why?
| | Injections, Intravenous | 1 | 2014 | 206 | 0.030 |
Why?
| | Pregnancy | 1 | 2007 | 6763 | 0.030 |
Why?
| | Mifepristone | 1 | 2014 | 64 | 0.030 |
Why?
| | Hormone Antagonists | 1 | 2014 | 34 | 0.030 |
Why?
| | Limbic System | 1 | 2014 | 47 | 0.030 |
Why?
| | src-Family Kinases | 1 | 2014 | 92 | 0.030 |
Why?
| | Biological Transport | 1 | 2014 | 418 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2014 | 346 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 1946 | 0.030 |
Why?
| | Models, Biological | 1 | 2020 | 1783 | 0.020 |
Why?
| | Amygdala | 1 | 2014 | 191 | 0.020 |
Why?
| | RNA Interference | 1 | 2014 | 469 | 0.020 |
Why?
| | Blotting, Western | 1 | 2014 | 1226 | 0.020 |
Why?
| | HEK293 Cells | 1 | 2014 | 730 | 0.020 |
Why?
| | Up-Regulation | 1 | 2014 | 843 | 0.020 |
Why?
| | Oxygen | 1 | 2014 | 931 | 0.020 |
Why?
| | Glucose | 1 | 2014 | 1020 | 0.020 |
Why?
| | Inositol 1,4,5-Trisphosphate | 1 | 2008 | 21 | 0.020 |
Why?
| | Mutation | 1 | 2020 | 3958 | 0.020 |
Why?
| | Microinjections | 1 | 2008 | 86 | 0.020 |
Why?
| | Muscarinic Antagonists | 1 | 2008 | 29 | 0.020 |
Why?
| | Biomarkers | 1 | 2020 | 4149 | 0.020 |
Why?
| | Paraventricular Hypothalamic Nucleus | 1 | 2007 | 32 | 0.020 |
Why?
| | Rats, Inbred Lew | 1 | 2007 | 114 | 0.020 |
Why?
| | Adrenalectomy | 1 | 2007 | 68 | 0.020 |
Why?
| | Restraint, Physical | 1 | 2007 | 72 | 0.020 |
Why?
| | Rats, Inbred Strains | 1 | 2007 | 362 | 0.020 |
Why?
| | Corticotropin-Releasing Hormone | 1 | 2007 | 68 | 0.020 |
Why?
| | Rats, Inbred F344 | 1 | 2007 | 265 | 0.020 |
Why?
| | Biosensing Techniques | 1 | 2008 | 129 | 0.020 |
Why?
| | Species Specificity | 1 | 2007 | 585 | 0.020 |
Why?
| | Transfection | 1 | 2008 | 945 | 0.020 |
Why?
| | Stress, Psychological | 1 | 2014 | 1100 | 0.020 |
Why?
| | Phenotype | 1 | 2014 | 3196 | 0.010 |
Why?
| | Eating | 1 | 2007 | 380 | 0.010 |
Why?
| | Stress, Physiological | 1 | 2007 | 443 | 0.010 |
Why?
| | Weight Gain | 1 | 2007 | 519 | 0.010 |
Why?
| | Body Composition | 1 | 2007 | 684 | 0.010 |
Why?
| | Circadian Rhythm | 1 | 2007 | 468 | 0.010 |
Why?
| | Hypoglycemia | 1 | 2007 | 445 | 0.010 |
Why?
| | RNA | 1 | 2008 | 921 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2009 | 2833 | 0.010 |
Why?
| | Adult | 1 | 2023 | 37929 | 0.010 |
Why?
| | Insulin | 1 | 2007 | 2409 | 0.010 |
Why?
|
|
Dabertrand's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|